Bioterrorism

Venatorx Pharmaceuticals Joins the Alliance for Biosecurity

Retrieved on: 
Jeudi, décembre 19, 2019
Research, Infectious diseases, Hospitals, FDA, Clinical trials, Biotechnology, Pharmaceutical, Health, Science, Other Science, Health, Alliance for Biosecurity, Bioterrorism, Pharmaceuticals policy, Biosecurity, Articles, Multiple drug resistance, Pharmaceutical industry in China

Venatorx Pharmaceuticals today announced that it joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies along with laboratory and academic partners that promotes a strong public-private partnership in order to ensure the medical countermeasures that protect public health are effective and readily available.

Key Points: 
  • Venatorx Pharmaceuticals today announced that it joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies along with laboratory and academic partners that promotes a strong public-private partnership in order to ensure the medical countermeasures that protect public health are effective and readily available.
  • We welcome Venatorx Pharmaceuticals to the Alliance, said Alliance for Biosecurity Co-Chair, Brent MacGregor.
  • Our 18 member companies, including Venatorx, provide a wide array of expertise and perspectives that contribute to our expanding scope.
  • Venatorx Pharmaceuticals is a private pharmaceutical company focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections.

The Good, The Bad and The Ugly - First Aid Global LLC Gives A Reality Check In The World of Pandemics

Retrieved on: 
Mardi, novembre 12, 2019
Infectious diseases, Medical specialties, Articles, RTT, Biological hazards, West African Ebola virus epidemic, Biological warfare, Global health, Ebola virus disease, Pandemic, Bioterrorism, Epidemic

The SNS has been expanded to include natural disasters like wildfires and hurricanes as well as emerging infectious diseases like Ebola or a deadly influenza epidemic.

Key Points: 
  • The SNS has been expanded to include natural disasters like wildfires and hurricanes as well as emerging infectious diseases like Ebola or a deadly influenza epidemic.
  • Supplies will be available for deployment in a bioterrorism or nuclear attack or against an infectious disease outbreak.
  • First Aid Global LLC carries their own comprehensive line of pandemic protection supplies that are available to both medical professionals and average families alike.
  • Having an adequate supply of survival items like food, water, first aid and personal protective equipment stockpiled in your own home is a smart idea."

Tonix Pharmaceuticals Joins the Alliance for Biosecurity

Retrieved on: 
Mardi, octobre 15, 2019
Bioterrorism, Alliance for Biosecurity, Biological warfare, Tonix Pharmaceuticals, Biosecurity, Biodefense, Biotechnology, Life sciences, Biology

NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has joined the Alliance for Biosecurity (the Alliance).

Key Points: 
  • NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has joined the Alliance for Biosecurity (the Alliance).
  • The Alliance advocates for public policies and funding to support the rapid development, production, stockpiling, and distribution of critically needed medical countermeasures.
  • Tonix has two programs in development to improve biodefense by potentially providing safe and effective countermeasures against possible biological and radiological threats.
  • "The Alliance for Biosecurity is pleased to welcome Tonix to our team, said Chris Frech, Co-Chair of the Alliance for Biosecurity.

SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on October 3, 2019

Retrieved on: 
Jeudi, septembre 26, 2019
Biological warfare, SIGA Technologies, Biodefense, Siga, Biotechnology, Bioterrorism, Alliance for Biosecurity, Life sciences, Biology

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGAs Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference at 3:00 p.m. EDT on Thursday, October 3, 2019 in New York.

Key Points: 
  • NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGAs Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference at 3:00 p.m. EDT on Thursday, October 3, 2019 in New York.
  • SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
  • Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness.
  • SIGA urges investors and security holders to read those documents free of charge at the SEC's web site at http://www.sec.gov.

SIGA to Present at the 14th Annual Wells Fargo Securities Healthcare Conference on September 5, 2019

Retrieved on: 
Mercredi, août 28, 2019
Biological warfare, Biodefense, Bioethics, SIGA Technologies, Biotechnology, Bioterrorism, Life sciences, Articles, Alliance for Biosecurity, Biomedical Advanced Research and Development Authority

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.

Key Points: 
  • SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
  • Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness.
  • This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
  • SIGA urges investors and security holders to read those documents free of charge at the SEC's web site at http://www.sec.gov .

Best-Selling Author Max Brooks And Blue Ribbon Study Panel on Biodefense Provide A 'Very Graphic History' Of Germ Warfare

Retrieved on: 
Jeudi, avril 25, 2019
Biological warfare, Bioethics, Bioterrorism, Blue Ribbon Study Panel on Biodefense, National security of the United States, Biodefense

WASHINGTON, April 25, 2019 /PRNewswire/ --Max Brooks, best-selling author of "World War Z" and non-resident fellow at the Modern War Institute at West Point, has partnered with the Blue Ribbon Study Panel on Biodefense to produce GERM WARFARE: A Very Graphic History.

Key Points: 
  • WASHINGTON, April 25, 2019 /PRNewswire/ --Max Brooks, best-selling author of "World War Z" and non-resident fellow at the Modern War Institute at West Point, has partnered with the Blue Ribbon Study Panel on Biodefense to produce GERM WARFARE: A Very Graphic History.
  • "Germs have always been our greatest enemy, and now they're more dangerous than ever," said Brooks.
  • "At the very moment some people are questioning vaccines, others are looking for ways to cook up the next pandemic in their basements.
  • That's why I agreed to write this graphic novel for the Blue Ribbon Study Panel on Biodefense, because the experts can't help us if we don't help ourselves.

Insights into the Global Biodefense Market 2019-2025: Segmented by Product & Region - ResearchAndMarkets.com

Retrieved on: 
Mercredi, avril 24, 2019
Health, Biotechnology, Biological warfare, Bioethics, Biodefense, CBRN defense, Emergent BioSolutions, SIGA Technologies, Biotechnology, Companies, Bioterrorism, Life sciences

The global biodefense market size is expected to reach USD 6.5 billion by 2025, growing at a CAGR of 4.5% over the forecast period.

Key Points: 
  • The global biodefense market size is expected to reach USD 6.5 billion by 2025, growing at a CAGR of 4.5% over the forecast period.
  • The market is majorly driven by rising focus of the public agencies on mitigating the risk of Chemical, Biological, Radiological and Nuclear (CBRN) threats and increased funding for biodefense.
  • Thus, rising risk of biological threats and subsequently rising R&D funding are augmenting the growth of this market.
  • It accounted for the second-largest revenue share in 2018
    Some of the key companies in the global market include PharmAthene, Inc.; Emergent BioSolutions, Inc.; SIGA Technologies, Inc.; and Xoma Corporation

The Global Market for Anthrax Treatment (2019-2023) - Bayer, Elusys Therapeutics and Emergent BioSolutions are the Leading Players

Retrieved on: 
Vendredi, décembre 14, 2018
Biological warfare, Medicine, Health, Biotechnology, Elusys Therapeutics, Anthrax, Bioterrorism, Vaccine

The "Global Anthrax Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anthrax Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The anthrax treatment market will register a CAGR of more than 8% by 2023.
  • The increase in funding for research on anthrax vaccine across the globe is likely to boost the market growth.
  • Several companies are developing vaccines and therapeutics for bioterrorism-associated anthrax including Elusys Therapeutics.

PathSensors Expands Into China, Announces Partnership with Radiusen

Retrieved on: 
Mardi, août 28, 2018
Biological warfare, Bioterrorism, Economy of China, Shenzhen

BALTIMORE, Md., Aug. 28, 2018 /PRNewswire-PRWeb/ -- PathSensors and Shenzhen Radiusen Systems Limited have entered into a partnership agreement to bring novel pathogen detection technologies to Chinese markets.

Key Points: 
  • BALTIMORE, Md., Aug. 28, 2018 /PRNewswire-PRWeb/ -- PathSensors and Shenzhen Radiusen Systems Limited have entered into a partnership agreement to bring novel pathogen detection technologies to Chinese markets.
  • PathSensors' CANARY technology will be distributed by Radiusen to customers in China with applications including bioterrorism, mail screening, food safety, and plant diagnostics.
  • "We've seen a dramatic increase in Chinese demand for high-tech diagnostic systems," commented PathSensors president Ted Olsen.
  • China is one of several international markets being explored by PathSensors as the company expands globally.